Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Xichun Hu
The addition of dimethyldiguanide might increase the efficacy of AI in patients with metastatic breast cancer after the failure of the first line endocrine therapy.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
postmenopausal HR positive breast cancer patients;
inoperable locally advanced or metastatic breast cancer patients;
candidate for endocrine therapy;
ECOG equal to or less than 1;
adequate bone marrow function(Hb\>=90g/L, WBC \>=3.5×10\^9/L,ANC\>=1.5×10\^9/L, PLT\>=80×10\^9/L; adequate renal function(Ccr\<=ULN);adequate liver function(ALT,AST,AKP\<=2.5\*ULN,or \<=5\*ULN if liver metastases)
life expectancy \>=12weeks;
no severe history disease of liver,heart,lung or kidney;
written informed consent form;
You may not be if
Her-2 overexpression;
patients who has visceral endocrisis；
Clareo Health | Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer
